Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Genitourinary 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Prostatic Neoplasms 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

Cytarabine 905Cyclophosphamide 899fludarabine 525venetoclax 489fludarabine phosphate 468Azacitidine 460Rituximab 431Methotrexate 419Etoposide 320Filgrastim 299Busulfan 296Dexamethasone 286Vincristine 285Daunorubicin 283Peripheral Blood Stem Cell Transplantation 258Whole-Body Irradiation 243Mycophenolic Acid 232Decitabine 230Granulocyte Colony-Stimulating Factor 227Tacrolimus 220Imatinib Mesylate 211Idarubicin 205Melphalan 202Cyclosporine 182Doxorubicin 177Radiotherapy 169Prednisone 164Dasatinib 163Mitoxantrone 161Lenalidomide 160

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Inosine Monophosphate × Other hematologic neoplasm × Clear all
NCT07474051 2026-03-16

PERSIST

AvenCell Therapeutics, Inc.

Enrolling by invitation
178 enrolled
GenitourinaryLymphoidOther hematologic neoplasm

Prostatic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms

NCT04230265 2026-01-22

Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

AvenCell Therapeutics, Inc.

Phase 1 Terminated
32 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡